Request Demo

Last update 14 Apr 2026

Crofelemer

Last update 14 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Polymer

Synonyms

CRO-HIV, CRO-IBS, CRO-ID

+ [11]

Target

ANO1 x CFTR

Action

inhibitors

Mechanism

ANO1 inhibitors(Anoctamin 1 inhibitors), CFTR inhibitors(Cystic fibrosis transmembrane conductance regulator inhibitors)

Therapeutic Areas

Other DiseasesNervous System DiseasesCongenital Disorders+ [3]

Active Indication

DiarrheaShort Bowel SyndromeMicrovillus Inclusion Disease+ [2]

Inactive Indication

Acquired Immunodeficiency SyndromeHerpes SimplexHIV Enteropathy

Originator Organization

Jaguar Health, Inc.

Active Organization

Napo Pharmaceuticals, Inc.

Napo Therapeutics SpA

National Institutes of Health

+ [1]

Inactive Organization

Shaman Pharmaceuticals, Inc.

Bausch Health Americas, Inc.

License Organization

Future Pak LLC

RedHill Biopharma Ltd.

Knight Therapeutics, Inc.

+ [6]

Drug Highest PhaseApproved

First Approval Date

United States (31 Dec 2012),

Diarrhea

RegulationOrphan Drug (United States), Orphan Drug (European Union), Fast Track (United States)

Clinical Trials associated with Crofelemer

NCT06904872

/ RecruitingPhase 2

A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)

A 24-week, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety and tolerability of crofelemer in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-continuity (CIC) requiring parenteral support (PS).
Blinded study drug will be administered orally (or enterally) three times daily (TID) as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution.
Patients will be randomized in a 1:1:1 ratio to crofelemer 3 mg/kg/dose TID, crofelemer 10 mg/kg/dose TID or placebo and randomization will be stratified by baseline PS volume (≤4 or >4 L/week).

Start Date29 May 2025

Sponsor / Collaborator

Napo Therapeutics SpA

NCT06721871

/ RecruitingPhase 2

Evaluation of Safety, Tolerability and Efficacy of Crofelemer Following Multiple Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Participants With Microvillus Inclusion Disease (MVID)

a 32-week study that will evaluate the safety, tolerability and preliminary efficacy of multiple ascending doses of crofelemer, compared to placebo, using a randomized cross-over design within each dose level, when administered to participants with MVID receiving parenteral support (PS, defined as TPN with or without supplementary IV fluid requirements). Blinded study drug will be administered as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution. Assigned study drug will be reconstituted and administered orally (or enterally) three times daily (TID) as a concentrated liquid formulation in each of the three dose levels

Start Date01 May 2025

Sponsor / Collaborator

Napo Pharmaceuticals, Inc.

NCT06326645

/ RecruitingEarly Phase 1IIT

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

The objectives of this study are to evaluate the efficacy and safety of crofelemer treatment in adults affected by Short Bowel Syndrome (SBS) with an ileostomy on parenteral support (PS) in reducing output or PS needs. Crofelemer will be provided as a powder three times daily for 12 weeks and a 4 week follow up. .

Start Date03 Mar 2025

Sponsor / Collaborator

The Cleveland Clinic Foundation

[+1]

100 Clinical Results associated with Crofelemer

100 Translational Medicine associated with Crofelemer

100 Patents (Medical) associated with Crofelemer

Literatures (Medical) associated with Crofelemer

01 Apr 2024·American journal of medical genetics. Part A

Clinical course and therapeutic trial for a case of congenital secretory diarrhea due to novel GUCY2C variant

Author: Horton, Darlene ; Teng, Ru-Jeng ; Wong, Ian Guo Yi ; Teng, Ru‐Jeng ; Scott, William ; Cramer, Jesse ; Muriello, Michael ; Basel, Donald ; Elkadri, Abdul

Abstract:

Chronic diarrhea presents a significant challenge for managing nutritional and electrolyte deficiencies, especially in children, given the higher stakes of impacting growth and developmental consequence. Congenital secretory diarrhea (CSD) compounds this further, particularly in the case of the activating variants of the guanylate‐cyclase 2C (GUCY2C) gene. GUCY2C encodes for the guanylate‐cyclase 2C (GC‐C) receptor that activates the downstream cystic fibrosis transmembrane receptor (CFTR) that primarily drives the severity of diarrhea with an unclear extent of influence on other intestinal channels. Thus far, management for CSD primarily consists of mitigating nutritional, electrolyte, and volume deficiencies with no known pathophysiology‐driven treatments. For activating variants of GUCY2C, experimental compounds have shown efficacy in vitro for direct inhibition of GC‐C but are not currently available for clinical use. However, Crofelemer, a CFTR inhibitory modulator with negligible systemic absorption, can theoretically help to treat this type of CSD. Herein, we describe and characterize the clinical course of a premature male infant with a de novo missense variant of GUCY2C not previously reported and highly consistent with CSD. With multi‐disciplinary family‐directed decision‐making, a treatment for CSD was evaluated for the first time to our knowledge with Crofelemer.

16 Oct 2023·The Journal of clinical investigation

Patient-derived enteroids provide a platform for the development of therapeutic approaches in microvillus inclusion disease

Article

Author: Kalashyan, Meri ; Thiagarajah, Jay R ; Bayer, Marie-Theres ; Roland, Joseph T ; Oller, Haley ; Shub, Mitchell D ; Kolobova, Elena ; Goldsmith, Jeffrey D ; Raghunathan, Krishnan ; Jimenez, Lissette ; Hagen, Susan J ; Kaji, Izumi ; Goldenring, James R

Microvillus inclusion disease (MVID), caused by loss-of-function mutations in the motor protein myosin Vb (MYO5B), is a severe infantile disease characterized by diarrhea, malabsorption, and acid/base instability, requiring intensive parenteral support for nutritional and fluid management. Human patient-derived enteroids represent a model for investigation of monogenic epithelial disorders but are a rare resource from MVID patients. We developed human enteroids with different loss-of function MYO5B variants and showed that they recapitulated the structural changes found in native MVID enterocytes. Multiplex immunofluorescence imaging of patient duodenal tissues revealed patient-specific changes in localization of brush border transporters. Functional analysis of electrolyte transport revealed profound loss of Na+/H+ exchange (NHE) activity in MVID patient enteroids with near-normal chloride secretion. The chloride channel-blocking antidiarrheal drug crofelemer dose-dependently inhibited agonist-mediated fluid secretion. MVID enteroids exhibited altered differentiation and maturation versus healthy enteroids. γ-Secretase inhibition with DAPT recovered apical brush border structure and functional Na+/H+ exchange activity in MVID enteroids. Transcriptomic analysis revealed potential pathways involved in the rescue of MVID cells including serum/glucocorticoid-regulated kinase 2 (SGK2) and NHE regulatory factor 3 (NHERF3). These results demonstrate the utility of patient-derived enteroids for developing therapeutic approaches to MVID.

01 Oct 2023·Clinical breast cancer

Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer

Article

Author: Melisko, Michelle ; Quintal, Laura ; Rugo, Hope S ; Johnson, MacKenzie ; Jacob, Saya ; Chien, Amy Jo ; Roque, Brianna

BACKGROUND:

To evaluate the efficacy of crofelemer, a first in class anti-secretory anti-diarrheal agent, to manage neratinib-induced diarrhea in patients with early-stage breast cancer taking adjuvant neratinib.

PATIENTS AND METHODS:

This single center, open label trial enrolled patients with Stage 2 to 3 HER2+ breast cancer taking adjuvant neratinib. One cohort took prophylactic crofelemer 125 mg bid and loperamide in the first 2 cycles, and as needed in subsequent cycles. The second cohort took dose-escalated neratinib with loperamide as needed (DE cohort). The primary endpoint was incidence of grade ≥ 3 diarrhea in the first 2 cycles.

RESULTS:

Seven patients in the crofelemer cohort and 4 in the DE cohort were enrolled. In the first 2 cycles, 2 patients (29%) in the crofelemer cohort and 2 patients (50%) in the DE cohort experienced grade 3 diarrhea lasting 1 day on average. After cycle 2, no additional patients in either cohort had grade 3 diarrhea. Five of 7 patients controlled diarrhea with crofelemer alone. There were no grade 4 diarrhea events in either cohort. Three patients in the crofelemer cohort dose-reduced neratinib due to diarrhea in the first 2 cycles. Patients in the crofelemer cohort had an average of 0.58 diarrhea episodes/day. 82% experienced constipation, all grade 1.

CONCLUSIONS:

This is the first study to investigate crofelemer for neratinib-induced diarrhea and demonstrates crofelemer activity in this setting. Further investigation of crofelemer for diarrhea secondary to cancer treatment is needed.

308

News (Medical) associated with Crofelemer

14 Apr 2026

·www.biospace.com

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health’s Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 2033 1 AI data mining of real world clinical and symptom manifestation is beneficial in the development of credible links between genetics, histopathology, and disease progression modification for intestinal failure (IF) patients with orphan disease designated pediatric microvillus inclusion disease (MVID) Jaguar seeking efficiencies to bring crofelemer to FDA approval for MVID-a disease with no alternative treatments and a lethal natural history SAN FRANCISCO, CA / ACCESS Newswire / April 13, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX ) today announced that it plans to use AI platforms to enhance its development, commercialization, and healthcare delivery objectives for crofelemer programs for the treatment of intestinal failure in both adult and pediatric patients. "Our IF program in MVID could leverage AI platforms that could help guide personalized regimens for each patient for this ultrarare disease and include real-world evidence to support the effectiveness and benefit of new therapies like crofelemer in mitigating disease progression by potentially providing credible links between genetics, histopathology, and clinical manifestation. AI platforms could lead to more efficient drug development and quicker access to drugs for patients with no alternative treatments for diseases with lethal natural history, such as MVID." said Pravin Chaturvedi, PhD, Jaguar's Chief Scientific Officer and Chair of the Jaguar Scientific Advisory Board. "We are strategically focused on demonstrating crofelemer's effectiveness and achieving faster commercialization to meet our healthcare delivery objectives for IF indications," said Lisa Conte, Jaguar's founder, president, and CEO. "Our IF development programs continue to make progress in meeting key clinical milestones, including the ground-breaking and consistent reduction of parenteral support of up to 37% in an investigator-sponsored MVID treatment program. We are currently in business development discussions with the goal of bringing in non-dilutive funds from potential partners. We are encouraged to report that our development plan for MVID could include a plan for obtaining Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) in the coming months, which would augment expedited regulatory submission pathways for this pediatric disorder. The very low prevalence of MVID and its lethal natural history without any available therapies underscores the need for rapid and efficient development and commercialization of crofelemer. In addressing this very serious unmet medical need, and we are exploring AI platforms to assist in achieving our objectives." About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome. For more information about: Jaguar Health, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company may utilize AI to support its intestinal failure program, and Jaguar's expectation that its development plan for MVID may support the possibility for a Breakthrough Therapy designation from the FDA in the coming months, potentially supporting opportunities for expedited regulatory submission pathways to the FDA for new drug approval. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 1 Global Short Bowel Syndrome Market - Size, Share, and Forecast (2025-2033) Contact: hello@jaguar.health Jaguar-JAGX SOURCE: Jaguar Health, Inc. View the original press release on ACCESS Newswire

Orphan DrugBreakthrough Therapy

13 Apr 2026

·jaguarhealth.gcs-web.com

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 20331 AI data mining of real world clinical and symptom manifestation is beneficial in the development of credible links between genetics, histopathology, and disease progression modification for intestinal failure (IF) patients with orphan disease designated pediatric microvillus inclusion disease (MVID) Jaguar seeking efficiencies to bring crofelemer to FDA approval for MVID-a disease with no alternative treatments and a lethal natural history SAN FRANCISCO, CA / ACCESS Newswire / April 13, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it plans to use AI platforms to enhance its development, commercialization, and healthcare delivery objectives for crofelemer programs for the treatment of intestinal failure in both adult and pediatric patients. "Our IF program in MVID could leverage AI platforms that could help guide personalized regimens for each patient for this ultrarare disease and include real-world evidence to support the effectiveness and benefit of new therapies like crofelemer in mitigating disease progression by potentially providing credible links between genetics, histopathology, and clinical manifestation. AI platforms could lead to more efficient drug development and quicker access to drugs for patients with no alternative treatments for diseases with lethal natural history, such as MVID." said Pravin Chaturvedi , PhD, Jaguar's Chief Scientific Officer and Chair of the Jaguar Scientific Advisory Board . "We are strategically focused on demonstrating crofelemer's effectiveness and achieving faster commercialization to meet our healthcare delivery objectives for IF indications," said Lisa Conte , Jaguar's founder, president, and CEO. "Our IF development programs continue to make progress in meeting key clinical milestones, including the ground-breaking and consistent reduction of parenteral support of up to 37% in an investigator-sponsored MVID treatment program. We are currently in business development discussions with the goal of bringing in non-dilutive funds from potential partners. We are encouraged to report that our development plan for MVID could include a plan for obtaining Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) in the coming months, which would augment expedited regulatory submission pathways for this pediatric disorder. The very low prevalence of MVID and its lethal natural history without any available therapies underscores the need for rapid and efficient development and commercialization of crofelemer. In addressing this very serious unmet medical need, and we are exploring AI platforms to assist in achieving our objectives." About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome. For more information about: Jaguar Health , visit https://jaguar.health Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company may utilize AI to support its intestinal failure program, and Jaguar's expectation that its development plan for MVID may support the possibility for a Breakthrough Therapy designation from the FDA in the coming months, potentially supporting opportunities for expedited regulatory submission pathways to the FDA for new drug approval. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 1Global Short Bowel Syndrome Market - Size, Share, and Forecast (2025-2033) Contact:hello@jaguar.healthJaguar-JAGX SOURCE: Jaguar Health, Inc.

Orphan DrugBreakthrough Therapy

09 Apr 2026

·jaguarhealth.gcs-web.com

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

Click here to register SAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) Participation Instructions for Webcast When: Friday, April 10, 2026 at 8:30 a.m. Eastern Participant Registration & Access Link: Click Here Replay Instructions for Webcast Replay of the webcast on the investor relations section of Jaguar's website: (click here) About the Jaguar Health Family of Companies Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health , visit https://jaguar.health Napo Therapeutics, visit napotherapeutics.com Magdalena Biosciences, visit magdalenabiosciences.com Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will hold an investor webcast on April 1, 2026 . In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@jaguar.healthJaguar-JAGX SOURCE: Jaguar Health, Inc.

100 Deals associated with Crofelemer

External Link

KEGG	Wiki	ATC	Drug Bank
D03605	Crofelemer	A07XA06	DB04941

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diarrhea	United States	Napo Pharmaceuticals, Inc.	31 Dec 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Enteropathy	Phase 3	United States	Bausch Health Americas, Inc.	01 Oct 2007
Acquired Immunodeficiency Syndrome	Phase 3	United States	Shaman Pharmaceuticals, Inc.	31 Aug 2001
Acquired Immunodeficiency Syndrome	Phase 3	Puerto Rico	Shaman Pharmaceuticals, Inc.	31 Aug 2001
Short Bowel Syndrome	Phase 2	Germany	Napo Therapeutics SpA	29 May 2025
Short Bowel Syndrome	Phase 2	Italy	Napo Therapeutics SpA	29 May 2025
Microvillus Inclusion Disease	Phase 2	United States	Napo Pharmaceuticals, Inc.	01 May 2025
Microvillus Inclusion Disease	Phase 2	Italy	Napo Pharmaceuticals, Inc.	01 May 2025
Microvillus Inclusion Disease	Phase 2	United Arab Emirates	Napo Pharmaceuticals, Inc.	01 May 2025
Irritable bowel syndrome with diarrhea	Phase 2	United States	Bausch Health Americas, Inc.	01 Dec 2004
Acute diarrhea	Phase 1	United States	Napo Pharmaceuticals, Inc.	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04486326 (CTgov)	Phase 4	Diarrhea	17	Crofelemer (Crofelemer)	qphoxlowlh(fpewcdwkqp) = jqnaclzmyx nogytuupaw (jbfxhsixdz, 0.72) View more	-	10 Mar 2026
				Placebo (Placebo)	qphoxlowlh(fpewcdwkqp) = rgobdsmvly nogytuupaw (jbfxhsixdz, 0.79) View more
NCT03898856 (CTgov)	Phase 4	Chronic diarrhea	93	Diagnostic tests for cause of chronic diarrhea+Crofelemer	jrmgjkpben = zhuiwoyxsq xzxdiqyfab (eghtqsbwiv, fxnefccxnv - lxwlfrxtuo) View more	-	12 Feb 2026
Company_Website Manual	Not Applicable	Microvillus Inclusion Disease	1	Crofelemer	znenummubf(tuytvygvwd) = ugankzdbmk gbctpotyng (tymrkkujyh )	Positive	20 May 2025
NCT04538625 (OnTARGET, Company_Website) Manual	Phase 3	Diarrhea	287	crofelemer	slyfynewik(gqmmsqhqxp) = crofelemer prophylaxis resulted in a greater proportion of monthly responders of diarrhea improvement compared to placebo. Overall, crofelemer was significantly more effective than placebo in providing sustained response in breast cancer patients dygvaciosv (yztsfxuleu ) Met	Positive	27 Mar 2025
				Placebo
NCT04538625 (OnTarget, Company_Website) Manual	Phase 3	Diarrhea	287	Crofelemer	pomdghdwqx(cakpdcoxvz) = cmwwxklrpk sjoekahvcf (raglebgumv )	Positive	12 Dec 2024
				Placebo	pomdghdwqx(cakpdcoxvz) = kvmdagqtgm sjoekahvcf (raglebgumv )
NCT04486326 (Company_Website) Manual	Phase 4	Diarrhea	-	Crofelemer	dxintjuhoo(zpxdxbrhdk) = statistically meaningful reduction ibtltsriwq (hiuvyfijbn )	Positive	28 May 2024
				Placebo
NCT02910219 (Pubmed) Manual	Phase 2	HER2 Positive Breast Cancer HER2 Positive	51	crofelemer	egluravsfx(xpclborehc) = wjrygcqnpz upcfywjggm (rnhaggagja ) View more	Negative	25 Oct 2022
				no scheduled prophylactic medication	egluravsfx(xpclborehc) = jirzlrinec upcfywjggm (rnhaggagja ) View more
NCT02910219 (HALT-D, CTgov)	Phase 2	Diarrhea	53	Crofelemer (Crofelemer)	zxoszhimdn = zfgpscgnpq zmtvhwuxvf (foauxwckna, cubqwiwbzf - ccvxwafsjd) View more	-	24 Oct 2022
				THP (Control)	zxoszhimdn = dbrqbgvpjl zmtvhwuxvf (foauxwckna, kpbdajolis - xuilazonyc) View more
NCT02910219 (Halt-d, SABCS2022)	Phase 2	Breast Cancer Neoadjuvant \| Adjuvant HER2+	53	Crofelemer	fjvlzhxntk(tppoiogjcd) = rtzybyymxy ipmevyhllh (siqcpfhwzc ) View more	Positive	15 Feb 2022
				Control	fjvlzhxntk(tppoiogjcd) = uohtonphwl ipmevyhllh (siqcpfhwzc ) View more
NCT02910219 (HALT-D, Company_Website) Manual	Phase 2	Diarrhea	51	Crofelemer	irogcciviu(xtmqyuxdrr) = not statistically different for the two groups vwofyszsfl (ijswtfzwut )	Negative	10 Dec 2021
				standard of care

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Crofelemer

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation